The Role of Inflammation in Early Left Ventricular Thrombus Formation Following ST-Elevation Myocardial Infarction-A Matched Case-Control Study.
Humans
ST Elevation Myocardial Infarction
/ blood
Male
Female
Middle Aged
Biomarkers
/ blood
Inflammation
/ blood
Thrombosis
/ blood
C-Reactive Protein
/ analysis
Aged
Heart Ventricles
/ diagnostic imaging
Risk Factors
Retrospective Studies
Leukocyte Count
Neutrophils
Time Factors
Case-Control Studies
LVT
STEMI
inflammation post myocardial infarction
left ventricular thrombus
Journal
Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
revised:
07
09
2024
received:
05
06
2024
accepted:
01
10
2024
medline:
16
10
2024
pubmed:
16
10
2024
entrez:
16
10
2024
Statut:
ppublish
Résumé
There is limited data on the association between inflammation and the formation of early left ventricular thrombus (LVT) following ST-elevation myocardial infarction (STEMI). This study aimed to explore the predictive value of several inflammatory biomarkers for LVT formation following STEMI. Our cohort included 2534 consecutive patients admitted to the cardiac intensive care unit (CICU) with STEMI. The final analysis included 51 patients with LVT and 102 patients without LVT, matched for age, sex, anterior infarct and ejection fraction. Upon admission, patients with LVT had higher white blood cell counts (WBC) (12.8 ± 7 vs. 12.4 ± 4 ×10 WBC and neutrophil counts upon admission, as well as peak WBC and CRP, have additional predictive value for LVT formation following STEMI, beyond classical risk factors.
Sections du résumé
BACKGROUND
BACKGROUND
There is limited data on the association between inflammation and the formation of early left ventricular thrombus (LVT) following ST-elevation myocardial infarction (STEMI). This study aimed to explore the predictive value of several inflammatory biomarkers for LVT formation following STEMI.
METHODS AND RESULTS
RESULTS
Our cohort included 2534 consecutive patients admitted to the cardiac intensive care unit (CICU) with STEMI. The final analysis included 51 patients with LVT and 102 patients without LVT, matched for age, sex, anterior infarct and ejection fraction. Upon admission, patients with LVT had higher white blood cell counts (WBC) (12.8 ± 7 vs. 12.4 ± 4 ×10
CONCLUSION
CONCLUSIONS
WBC and neutrophil counts upon admission, as well as peak WBC and CRP, have additional predictive value for LVT formation following STEMI, beyond classical risk factors.
Substances chimiques
Biomarkers
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e70031Informations de copyright
© 2024 The Author(s). Clinical Cardiology published by Wiley Periodicals, LLC.
Références
S. Khoury, S. Carmon, G. Margolis, G. Keren, and Y. Shacham, “Incidence and Outcomes of Early Left Ventricular Thrombus Following ST‐Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention,” Clinical Research in Cardiology 106, no. 9 (2017): 695–701.
E. Nikolsky, R. Mehran, G. D. Dangas, et al., “Outcomes of Patients Treated With Triple Antithrombotic Therapy After Primary Percutaneous Coronary Intervention for ST‐Elevation Myocardial Infarction (From the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS‐AMI] Trial),” American journal of cardiology 109, no. 6 (2012): 831–838.
S. Gianstefani, A. Douiri, I. Delithanasis, et al., “Incidence and Predictors of Early Left Ventricular Thrombus After ST‐Elevation Myocardial Infarction in the Contemporary Era of Primary Percutaneous Coronary Intervention,” American Journal of Cardiology 113, no. 7 (2014): 1111–1116.
Y. Shacham, E. Leshem‐Rubinow, E. Ben Assa, et al., “Frequency and Correlates of Early Left Ventricular Thrombus Formation Following Anterior Wall Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention,” American Journal of Cardiology 111, no. 5 (2013): 667–670.
J. W. Weinsaft, H. W. Kim, A. L. Crowley, et al., “LV Thrombus Detection by Routine Echocardiography,” JACC: Cardiovascular Imaging 4, no. 7 (2011): 702–712.
L. E. Rabbani, C. Waksmonski, S. N. Iqbal, et al., “Determinants of Left Ventricular Thrombus Formation After Primary Percutaneous Coronary Intervention for Anterior Wall Myocardial Infarction,” Journal of Thrombosis and Thrombolysis 25, no. 2 (2008): 141–145.
M. Zielinska, K. Kaczmarek, and M. Tylkowski, “Predictors of Left Ventricular Thrombus Formation in Acute Myocardial Infarction Treated With Successful Primary Angioplasty With Stenting,” American Journal of the Medical Sciences 335, no. 3 (2008): 171–176.
A. Kalra and I. K. Jang, “Prevalence of Early Left Ventricular Thrombus After Primary Coronary Intervention for Acute Myocardial Infarction,” Journal of Thrombosis and Thrombolysis 10, no. 2 (2000): 133–136.
S. Domenicucci, F. Chiarella, P. Bellotti, G. Lupi, G. Scarsi, and C. Vecchio, “Early Appearance of Left Ventricular Thrombi After Anterior Myocardial Infarction: A Marker of Higher In‐Hospital Mortality in Patients Not Treated With Antithrombotic Drugs,” European Heart Journal 11, no. 1 (1990): 51–58.
N. Frangogiannis, “The Inflammatory Response in Myocardial Infarction,” Cardiovascular Research 53, no. 1 (2002): 31–47.
Y. Seo, H. Maeda, T. Ishizu, et al., “Peak C‐Reactive Protein Concentration Correlates With Left Ventricular Thrombus Formation Diagnosed by Contrast Echocardiographic Left Ventricular Opacification in Patients With a First Anterior Acute Myocardial Infarction,” Circulation Journal 70, no. 10 (2006): 1290–1296.
T. Anzai, T. Yoshikawa, H. Kaneko, et al., “Association Between Serum C‐Reactive Protein Elevation and Left Ventricular Thrombus Formation After First Anterior Myocardial Infarction,” Chest 125, no. 2 (2004): 384–389.
Ş. Çlelik, M. Baykan, C. Erdöul, et al., “C‐Reactive Protein as a Risk Factor for Left Ventricular Thrombus in Patients With Acute Myocardial Infarction,” Clinical Cardiology 24, no. 9 (2001): 615–619.
K. Thygesen, J. S. Alpert, A. S. Jaffe, et al., “Fourth Universal Definition of Myocardial Infarction (2018),” European Heart Journal 40, no. 3 (2019): 237–269.
N. B. Schiller, P. M. Shah, M. Crawford, et al., “Recommendations for Quantitation of the Left Ventricle by Two‐Dimensional Echocardiography,” Journal of the American Society of Echocardiography 2, no. 5 (1989): 358–367.
I. Lechner, M. Reindl, C. Tiller, et al., “Association Between Inflammation and Left Ventricular Thrombus Formation Following ST‐Elevation Myocardial Infarction,” International Journal of Cardiology 361 (2022): 1–6.
R. Dragu, S. Huri, R. Zukermann, et al., “Predictive Value of White Blood Cell Subtypes for Long‐Term Outcome Following Myocardial Infarction,” Atherosclerosis 196, no. 1 (2008): 405–412.
Y. Shacham, E. Leshem‐Rubinow, E. Ben Assa, et al., “Comparison of C‐Reactive Protein and Fibrinogen Levels in Patients Having Anterior Wall ST‐Segment Elevation Myocardial Infarction With Versus Without Left Ventricular Thrombus (From a Primary Percutaneous Coronary Intervention Cohort),” American Journal of Cardiology 112, no. 1 (2013): 57–60.
R. Delewi, R. Nijveldt, A. Hirsch, et al., “Left Ventricular Thrombus Formation After Acute Myocardial Infarction as Assessed by Cardiovascular Magnetic Resonance Imaging,” European Journal of Radiology 81, no. 12 (2012): 3900–3904.
W. K. Lagrand, H. W. M. Niessen, G. J. Wolbink, et al., “C‐Reactive Protein Colocalizes With Complement in Human Hearts During Acute Myocardial Infarction,” Circulation 95, no. 1 (1997): 97–103.
M. Griselli, J. Herbert, W. L. Hutchinson, et al., “C‐Reactive Protein and Complement Are Important Mediators of Tissue Damage in Acute Myocardial Infarction,” Journal of Experimental Medicine 190, no. 12 (1999): 1733–1740.
R. Nijmeijer, W. K. Lagrand, Y. T. P. Lubbers, et al., “C‐Reactive Protein Activates Complement in Infarcted Human Myocardium,” American Journal of Pathology 163, no. 1 (2003): 269–275.
P. M. Ridker, M. Cushman, M. J. Stampfer, R. P. Tracy, and C. H. Hennekens, “Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men,” New England Journal of Medicine 336, no. 14 (1997): 973–979.
T. Katayama, H. Nakashima, C. Takagi, et al., “Predictors of Sub‐Acute Stent Thrombosis in Acute Myocardial Infarction Patients Following Primary Coronary Stenting With Bare Metal Stent,” Circulation Journal 70, no. 2 (2006): 151–155.
P. M. Ridker, C. H. Hennekens, J. E. Buring, and N. Rifai, “C‐Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women,” New England Journal of Medicine 342, no. 12 (2000): 836–843.
S. M. Boekholdt, C. E. Hack, M. S. Sandhu, et al., “C‐Reactive Protein Levels and Coronary Artery Disease Incidence and Mortality in Apparently Healthy Men and Women: The EPIC‐Norfolk Prospective Population Study 1993‐2003,” Atherosclerosis 187, no. 2 (2006): 415–422.
P. M. Ridker, N. Rifai, L. Rose, J. E. Buring, and N. R. Cook, “Comparison of C‐Reactive Protein and Low‐Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events,” New England Journal of Medicine 347, no. 20 (2002): 1557–1565.
P. M. Ridker, N. Rifai, M. Clearfield, et al., “Measurement of C‐Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events,” New England Journal of Medicine 344, no. 26 (2001): 1959–1965.
P. M. Ridker, E. Danielson, F. A. H. Fonseca, et al., “Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C‐Reactive Protein,” New England Journal of Medicine 359, no. 21 (2008): 2195–2207.
G. N. Levine, J. W. McEvoy, J. C. Fang, et al., “Management of Patients at Risk for and With Left Ventricular Thrombus: A Scientific Statement From the American Heart Association,” Circulation 146, no. 15 (2022): e205–e223.
P. T. O'Gara, F. G. Kushner, D. D. Ascheim, et al., “ACCF/AHA Guideline for the Management of ST‐Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Circulation 2013 127, no. 4 (2013): e362–e425.
A. Camaj, V. Fuster, G. Giustino, et al., “Left Ventricular Thrombus Following Acute Myocardial Infarction,” Journal of the American College of Cardiology 79, no. 10 (2022): 1010–1022.
J. C. Tardif, S. Kouz, D. D. Waters, et al., “Efficacy and Safety of Low‐Dose Colchicine After Myocardial Infarction,” New England Journal of Medicine 381, no. 26 (2019): 2497–2505.
J. W. Weinsaft, J. Kim, C. B. Medicherla, et al., “Echocardiographic Algorithm for Post‐Myocardial Infarction LV Thrombus,” JACC: Cardiovascular Imaging 9, no. 5 (2016): 505–515.
A. B. Osherov, M. Borovik‐Raz, D. Aronson, et al., “Incidence of Early Left Ventricular Thrombus After Acute Anterior Wall Myocardial Infarction in the Primary Coronary Intervention Era,” American Heart Journal 157, no. 6 (2009): 1074–1080.
S. Solheim, I. Seljeflot, K. Lunde, et al., “Frequency of Left Ventricular Thrombus in Patients With Anterior Wall Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention and Dual Antiplatelet Therapy,” American Journal of Cardiology 106, no. 9 (2010): 1197–1200.